Company Monitoring Page for Shire

latest headlines for company on cafepharma

FDA OKs CSL’s new HAE drug, already embroiled in a blockbuster fight with Shire
Endpoints
Fri, 06/23/17 - 09:48 am
Tags:
FDA, CSL, HAE, hereditary angiodema, Shire, Haegarda, Firazyr, Kalbito
A decade behind schedule, Shire finally gets an FDA OK for long-acting ADHD drug
Endpoints
Wed, 06/21/17 - 09:50 am
Tags:
Shire, FDA, ADHD, Mydayis, SHP465
Kamada slumps after Shire hands back rights
BioPharma Dive
Thu, 06/8/17 - 10:05 pm
Tags:
Shire, Kamada, alpha-1 antitrypsin, graft vs host disease
Shire Is Poised To Dominate The HAE Market After Strong Phase III Data For SHP643
Seeking Alpha
Mon, 05/22/17 - 07:43 pm
Tags:
Shire, HAE, SHP643, lanadelumab
Shire writes off a shot at long-acting hemophilia drug after small study flops
Endpoints
Mon, 05/22/17 - 09:55 am
Tags:
Shire, hemophilia A, SHP656, Xenetic Biosciences, clinical trials
Shire’s multibillion-dollar gamble on lanadelumab pays off with stellar PhIII data, quick marketing application
Endpoints
Thu, 05/18/17 - 09:38 am
Tags:
Shire, lanadelumab, DX-2930, HAE, Cinryze, Dyax
Shire commits up to $535M for Parion's dry eye drug
BioPharma Dive
Tue, 05/2/17 - 11:16 am
Tags:
Shire, Parion, dry eye disease, P-321
Shire, armed with new rare disease patent, aims to block CSL's Haegarda launch
Fierce Pharma
Mon, 04/17/17 - 04:10 pm
Tags:
Shire, rare disease, CSL, patents, Haegarda, HAE, hereditary angiodema
Shire's DTC move to scrap smiling patients for double 'i's pays off—and it thinks other pharmas should take note
Fierce Pharma
Thu, 04/13/17 - 09:39 am
Tags:
Shire, DTC ads, patients, Xiidra, dry eye disease
About that pharma M&A comeback? Sorry. 2017's not bringing it—at least not yet
Fierce Pharma
Mon, 04/10/17 - 10:19 am
Tags:
M&A, Stada, Shire, Baxalta, JNJ, Actelion, Mylan Labs, Pfizer, Takeda, Ariad Pharmaceuticals, Medivation
Shire Rises on Encouraging Angioedema Results
TheStreet.com
Thu, 02/23/17 - 09:25 pm
Tags:
Shire, angioedema, lanadelumab
2016 went out like a lamb in the biopharma M&A world. Will it roar back in 2017? Plus, top 10 deals
Endpoints
Wed, 02/22/17 - 11:43 am
Tags:
M&A, Shire, Baxalta, Pfizer, Medivation, Mylan, Meda, AbbVie, Stemcentrx, Anacor
Baxalta pushes Shire to record revenues
BioPharma Dive
Thu, 02/16/17 - 03:18 pm
Tags:
Shire, Baxalta, earnings
Shire finally finishes a 10-year trek back to the FDA with an old ADHD drug
Endpoints
Thu, 01/19/17 - 11:49 am
Tags:
Shire, FDA, ADHD, SHP465
Shire to pay $350 million for kickback allegations
Marketwatch
Thu, 01/12/17 - 09:14 am
Tags:
Shire, kickbacks, False Claims Act, Dermagraft
Shire deals RNA platform to Cambridge's RaNa for equity stake
Bizjournals.com
Wed, 01/4/17 - 10:44 am
Tags:
Shire, RNA, RaNA, drug development
Allergan Is Losing Its No. 2 Product More Rapidly Than Expected
Seeking Alpha
Wed, 12/21/16 - 10:53 am
Tags:
Allergan, dry eye disease, Restasis, Shire, Xiidra
The Most Expensive Drugs of 2016
Motley Fool
Mon, 12/19/16 - 11:32 am
Tags:
drug pricing, Gilead Sciences, Harvoni, Sovaldi, H.P. Acthar, Mallinckrodt, Shire, Cinryze, Daklinza, Bristol-Myers Squibb
Shire's Vonvendi controls surgical bleeding
BioPharma Dive
Mon, 12/5/16 - 01:31 pm
Tags:
Shire, Vonvendi, surgical bleeding
Allergan's Restasis Faces Dry Eye Threat: Examining XIIDRA's Initial Sales Trends
Seeking Alpha
Tue, 11/8/16 - 10:09 am
Tags:
Allergan, dry eye disease, Restasis, Xiidra, Shire

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.